- Report
- January 2026
- 160 Pages
Global
From €3030EUR$3,358USD£2,633GBP
€3565EUR$3,950USD£3,097GBP
- Report
- October 2025
- 160 Pages
Global
From €3030EUR$3,358USD£2,632GBP
€3565EUR$3,950USD£3,097GBP
- Report
- October 2025
- 160 Pages
Global
From €3030EUR$3,358USD£2,632GBP
€3565EUR$3,950USD£3,097GBP
- Report
- October 2025
- 160 Pages
Global
From €3030EUR$3,358USD£2,632GBP
€3565EUR$3,950USD£3,097GBP
- Report
- February 2026
- 99 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Report
- February 2026
- 95 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Report
- January 2026
- 127 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Report
- September 2025
- 87 Pages
Global
From €3500EUR$4,155USD£3,147GBP
- Report
- January 2026
- 140 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- June 2025
- 145 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- February 2026
- 202 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- January 2026
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- December 2025
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- September 2025
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- July 2025
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- July 2025
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- May 2025
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- April 2025
- 150 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- October 2025
- 89 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- August 2025
- 115 Pages
Global
From €3113EUR$3,450USD£2,705GBP

Single Use Bioreactors (SUBs) are bioreactors that are designed for a single use and then disposed of. They are used in biotechnology for the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. SUBs are typically made of plastic and are pre-sterilized, eliminating the need for cleaning and sterilization between batches. This makes them ideal for rapid scale-up and production of biopharmaceuticals. SUBs also offer advantages such as reduced risk of contamination, improved process control, and reduced capital costs.
The SUB market is growing rapidly due to the increasing demand for biopharmaceuticals and the need for rapid scale-up and production. SUBs are becoming increasingly popular in the biotechnology industry due to their cost-effectiveness and convenience.
Some companies in the SUB market include Sartorius, Thermo Fisher Scientific, Merck KGaA, GE Healthcare, and Pall Corporation. Show Less Read more